TearLab Corporation (NASDAQ:TEAR) expects to announce its Q1 2014 financial results after market closes on Thursday May 8, 2014. TearLab Corporation (NASDAQ:TEAR) is pleased to invite all willing participants in a conference call during which time financial results will be discussed. TearLab Corp (NASDAQ:TEAR) stock performance was -7.61% in last session and finished the day at $4.98. Traded volume was 779,893.00million shares in the last session and the average volume of the stock remained 472.77K shares. The beta of the stock remained 2.55. TearLab Corp (NASDAQ:TEAR) insider ownership is 0.40%.
Galectin Therapeutics Inc (NASDAQ:GALT) Director Steven Prelack sold 6,000 shares of the company’s stock in a transaction that occurred on Friday, April 11th. The shares were sold at an average price of $11.84, for a total transaction of $71,040.00. Following the transaction, the director now directly owns 87,219 shares in the company, valued at approximately $1,032,673. Galectin Therapeutics Inc. (NASDAQ:GALT) dropped -5.86 percent to $10.28 Wednesday on volume of 293,794.00million shares. The intra-day range of the stock was $10.21 to $11.16. Galectin Therapeutics Inc. (NASDAQ:GALT) has a market capitalization of $239.51million.
Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, announced that Gregory Weaver, senior vice president and chief financial officer of Fibrocell Science Inc. (NYSE MKT:FCSC), will present at the Alliance for Regenerative Medicine’s (ARM) 2(nd) Annual Regen Med Investor Day at the Metropolitan Club in New York, and the BioCentury Future Leaders in the Biotech Industry conference at the Millennium Broadway Hotel & Conference Center in New York. Mr. Weaver discussed the company’s autologous fibroblast technology, its therapeutic candidates in development, and its collaboration with Intrexon Corporation (NYSE: XON) to develop genetically-modified personalized biologics. Fibrocell Science Inc (NYSEMKT:FCSC)’s stock on Apr 16, 2014 reported a decrease of -8.16% to the closing price of $4.05. Its fifty two weeks range is $3.03 -$7.20. The total market capitalization recorded $165.39million. The overall volume in the last trading session was 174,167.00million shares. In its share capital, FCSC has 40.84million outstanding shares.
Bothell based BioLife Solutions, Inc. (NASDAQ:BLFS) announced April 16 preliminary revenue of $2 million for the first quarter of 2014. Proprietary product revenue shipments were $1.13 million, representing 71 percent growth during the same period in 2013. On Wednesday, shares of BioLife Solutions Inc (NASDAQ:BLFS) dropped -6.15% to close the day at $3.66. Company return on investment (ROI) is 11.10% and its monthly performance is recorded as -33.45%. BioLife Solutions Inc (NASDAQ:BLFS) quarterly revenue growth is -56.43%.